Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Repurchased
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Gross PP&E Adjustments (2023 - 2025)

Historic Other Gross PP&E Adjustments for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $47.7 million.

  • Tonix Pharmaceuticals Holding's Other Gross PP&E Adjustments rose 440.3% to $47.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.7 million, marking a year-over-year increase of 440.3%. This contributed to the annual value of $36.6 million for FY2024, which is 5852.98% down from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Other Gross PP&E Adjustments of $47.7 million as of Q3 2025, which was up 440.3% from $47.0 million recorded in Q2 2025.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's Other Gross PP&E Adjustments peaked at $98.6 million during Q1 2024, and registered a low of $36.6 million during Q4 2024.
  • Its 3-year average for Other Gross PP&E Adjustments is $68.0 million, with a median of $47.7 million in 2025.
  • Its Other Gross PP&E Adjustments has fluctuated over the past 5 years, first tumbled by 5852.98% in 2024, then surged by 440.3% in 2025.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Other Gross PP&E Adjustments (Quarter) stood at $88.3 million in 2023, then tumbled by 58.53% to $36.6 million in 2024, then surged by 30.37% to $47.7 million in 2025.
  • Its Other Gross PP&E Adjustments was $47.7 million in Q3 2025, compared to $47.0 million in Q2 2025 and $45.9 million in Q1 2025.